title: Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine.
abstract: BACKGROUND
  Levosimendan is a relatively new cardiac inotropic agent with calcium sensitizing activity. This study was conducted to investigate the effects of levosimendan (L) and dobutamine (D) on renal function in patients hospitalized with decompensated heart failure (HF).
  
  
  METHODS
  The present study included 88 consecutive patients hospitalized with acutely decompensated HF (New York Heart Association (NYHA) Class 3-4) requiring inotropic therapy. Patients were randomized 2:1 to either L or D for intravenous inotropic support. Diuretic therapy was kept constant during infusions. Renal function values, including serum creatinine (CR), blood urea nitrogen, 24-h urinary output levels and calculated glomerular filtration rate (GFR) were measured just prior to and 24 h after the infusions in all patients, and 48 and 72 h after the infusions in every second patient in both groups. The pre and post-infusion values of renal function and left ventricular ejection fraction (LVEF) were evaluated.
  
  
  RESULTS
  LVEF increased significantly in both groups. Those in L showed a significant improvement in calculated GFR after 24 h, whereas those in D showed no significant change (median in change in L:+15.3%, median change in D: -1.33%). Furthermore, in the L group a significant improvement was observed in calculated GFR after 72 h compared to baseline levels, whereas in D no significant change (median change in L:+45.45%, median change in D: +0.09%) was seen. Both agents improved 24-h urinary output.
  
  
  CONCLUSIONS
  Levosimendan seems to provide beneficial effects in terms of improvement in renal function compared to dobutamine in patients with heart failure who require inotropic therapy.
authors.affiliation: Department of Cardiology, Cumhuriyet University Faculty of Medicine, 584140, Sivas, Turkey. cardioceptor@gmail.com
authors.forename: Mehmet Birhan
authors.initials: MB
authors.lastname: Yilmaz
authors.forename: Kenan
authors.initials: K
authors.lastname: Yalta
authors.forename: Can
authors.initials: C
authors.lastname: Yontar
authors.forename: Filiz
authors.initials: F
authors.lastname: Karadas
authors.forename: Alim
authors.initials: A
authors.lastname: Erdem
authors.forename: Okan Onur
authors.initials: OO
authors.lastname: Turgut
authors.forename: Ahmet
authors.initials: A
authors.lastname: Yilmaz
authors.forename: Izzet
authors.initials: I
authors.lastname: Tandogan
mesh_terms: D000208:Acute Disease; D000368:Aged; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004280:Dobutamine / Q000494:pharmacology*; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006835:Hydrazones / Q000494:pharmacology*; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011724:Pyridazines / Q000494:pharmacology*; D000077464:Simendan; D014554:Urination / Q000187:drug effects
chemical_list: D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D000077464:Simendan; D004280:Dobutamine